Clinical trial · Interventional
Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients
Multicenter, Randomized, Controlled, Prospective, Confirmatory Study to Evaluate the Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients Confidential Statement
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial aims to evaluate whether an augmented reality (AR)-based medical imaging solution (SKIA-Breast) is non-inferior to conventional ultrasound-guided skin marking in guiding breast-conserving surgery in female patients with breast cancer. Participants will be randomly assigned in a 1:1 ratio to either the AR-based group or the conventional group. All participants will undergo breast-conserving surgery according to their assigned method. The primary outcome is the negative margin resection rate evaluated by histopathological examination. The secondary outcome is the re-excision rate due to positive margins assessed by histopathological examination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| General ultrasound imaging system | Device | — | UNRESOLVED |
| Surgical navigation system with stereotactic guidance | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Ultrasound Skin Marking Group
- description
- Mastectomy will be performed after applying the ultrasound skin marking method
- interventionNames
- Device: General ultrasound imaging system
- type
- EXPERIMENTAL
- label
- AR-based Imaging Group
- description
- Mastectomy will be performed after applying the localization method using the augmented reality-based medical imaging solution
- interventionNames
- Device: Surgical navigation system with stereotactic guidance
Primary outcomes (1)
- measure
- Negative margin resection rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects will be enrolled only when all the inclusion criteria are fully met. 1. Subjects who aged 19 to 80 years diagnosed with breast cancer through biopsy. 2. Subjects diagnosed with breast cancer who had both MRI and CT and ultrasound scans. 3. Patients diagnosed with breast cancer who are scheduled to undergo breast-conserving surgery, have not received neoadjuvant chemotherapy, and show no evidence of metastasis to other organs. 4. Tumor size criteria on ultrasound: : 5 mm ≤ tumor size ≤ 30 mm 5. Subjects whose biopsy pathology results are Invasive carcinoma. 6. Subjects who have a single lesion. 7. Subjects who have received a full explanation of the clinical trial fully understand its details, voluntarily decide to participate, and provide written informed consent. Exclusion Criteria: * Subjects will be excluded from enrollment if they meet any of the exclusion criteria. 1. Subjects prohibited from both MRI, CT and Ultrasound scans. 2. Subjects with no lesions visible on CT. 3. Pregnant or lactating(i.e., breastfeeding) subjects. 4. Subjects who are biologically male. 5. Subjects with breast cancer who received neoadjuvant chemotherapy or who have metastasized to other organs 6. Subjects whose biopsy pathology results are Invasive lobular carcinoma 7. Subjects deemed unsuitable for the study according to judgment of the investigator
References
Publications (0)
Data not yet available